David Amsellem
About David Amsellem
David Amsellem serves as the Managing Director and Senior Analyst for Specialty Pharmaceuticals at Piper Sandler, where he provides investment insights to institutional clients in North America and Europe. With nearly two decades of experience in sell-side equity research, he specializes in both brand and generic pharmaceutical companies.
Work at Piper Sandler
David Amsellem has served as Managing Director and Senior Analyst in Specialty Pharmaceuticals at Piper Sandler since 2008. In this role, he covers a diverse range of pharmaceutical companies, focusing on both brand and generic pharmaceuticals. He provides institutional clients in North America and Europe with proprietary investment ideas, leveraging nearly two decades of experience in sell-side equity research. His work includes publishing institutional equity research that spans various market capitalizations within the specialty pharmaceutical sector.
Previous Experience at FBR
Before joining Piper Sandler, David Amsellem worked at FBR for a total of five years. He held the position of Vice President from 2006 to 2008 and served as a Research Associate from 2003 to 2006. During his tenure at FBR, he developed expertise in equity research, specifically targeting pharmaceutical and biotechnology companies, which contributed to his career advancement in the financial sector.
Education and Expertise
David Amsellem earned a Bachelor of Science degree from Cornell University, where he studied from 1994 to 1998. His educational background laid the foundation for his nearly two decades of experience in sell-side equity research, particularly in the pharmaceutical and biotechnology sectors. His expertise includes identifying emerging products and technologies within the pharmaceutical industry, which informs his investment strategies.
Industry Focus and Research
Amsellem focuses on providing institutional clients with insights into the pharmaceutical sector. His research covers a broad spectrum of companies, including those involved in specialty pharmaceuticals. He emphasizes proprietary investment ideas and has a significant interest in emerging products and technologies that can impact the market. His analytical work aids clients in making informed investment decisions.